Hunan Jingfeng Pharmaceutical Co.Ltd(000908) on December 23, it was announced that the subsidiary Beijing pudekangli Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as “pudekangli”) obtained the drug registration approval of the chemical “flurbiprofen axetil injection” approved and issued by the State Drug Administration. The product is registered and declared by Shanxi Pude Pharmaceutical Co., Ltd. entrusted by Pude Kangli. Product approval helps to optimize the company’s product structure and improve market competitiveness.
It is understood that flurbiprofen axetil injection belongs to non steroidal anti-inflammatory analgesics. Clinically, it is used for postoperative and cancer analgesia. It can effectively control pain, no longer have addiction, and has no central inhibitory effect, which is conducive to the postoperative recovery of patients.
Hunan Jingfeng Pharmaceutical Co.Ltd(000908) said that the approval will not have a significant impact on the company’s recent performance. The company will actively carry out the production and sales of the product in accordance with the measures for the administration of drug registration and relevant regulations.
(Shanghai Securities News · China Securities Network)
